Navigation Links
Experiments could lead to new treatments for neuroblastoma
Date:8/15/2008

GALVESTON, Texas Neuroblastoma is one of the most devastating diagnoses a child can receive. The cancer's victims average 2 years old when the disease is detected, most often by a parent feeling a lump in a child's abdomen. By then, the disease has often reached an advanced stage, and advanced neuroblastoma kills more than 50 percent of the children in whom it develops, despite aggressive treatment with surgery, chemotherapy and radiation.

Now, though, University of Texas Medical Branch at Galveston researchers believe they've found a critical weakness in the deadly cancer one that could lead to the development of a lifesaving therapy. In a paper published this week in the "Proceedings of the National Academy of Sciences," a team led by associate professor of surgery Dr. Dai H. Chung describes cell-culture and animal experiments that demonstrate how shutting down a single biochemical signaling connection dramatically suppresses neuroblastoma tumor formation and slows the cancer's spread.

Their investigation centered on an intercellular signaling molecule known as gastrin-releasing peptide, or GRP, and the receptor molecule with which it docks on the cell's surface. GRP activates the production of gastrin, a hormone that among other things controls the release of gastric acid in the stomach; GRP is also produced by neuroblastoma cells and acts to accelerate their proliferation, a discovery made earlier by the UTMB group.

"We had previously demonstrated that GRP stimulates the growth of this particular cancer," said Chung. "This time we wanted to demonstrate the opposite effects by targeting GRP receptors in neuroblastoma, to see if we could make the cancer regress."

To "target" GRP, the researchers took a line of aggressive human neuroblastoma cells and added short-hairpin RNAs, tiny bits of genetic material specifically designed to keep cells from making particular proteins in this case GRP receptor molecules. Experiments with the GRP-receptor-silenced human neuroblastoma cells revealed that they grew much less quickly than unaltered neuroblastoma cells, and showed less activity on a biochemical signaling pathway that is associated with abnormal cell proliferation.

The scientists then cultured the customized cells in soft agar, a gelatin-like material that gave them no surface to which they could attach themselves. Most cells need be solidly anchored to multiply and form colonies, but neuroblastoma cells (like other cancer cells) thrive in soft agar suspension

"In order for cells in a soft agar colony to proliferate and grow without adhering to a surface, they have to possess malignant properties, as in the original neuroblastoma cells," Chung said. "However, our GRP receptor-silenced neuroblastoma cells behaved like nonmalignant cells their growth was significantly inhibited, and they formed fewer new colonies."

To further test what effect blocking GRP/GRP receptor binding would have on neuroblastoma in experimental animals, the researchers injected their GRP receptor-silenced neuroblastoma cells into immune-deficient mice. "We wanted to see how these neuroblastoma cells would behave, whether they would grow and/or metastasize to the liver," Chung said. "But instead, tumor growth was significantly attenuated." In control group mice, by contrast, "the cancer cells that expressed the GRP receptors behaved as we expected with rapid growth as well as aggressive liver metastases. The implication is that the metastatic behavior of this cancer is driven by GRP and its receptor."

Although researchers are discussing the use of short-hairpin RNA and other RNA interference techniques as potential therapies for patients with neuroblastoma and other cancers, Chung said, a compound that blocks the GRP receptor has already been approved by the FDA for adult use.

"With the publication of our data, we would like to propose an application involving a number of institutions to move forward with a phase 1 clinical trial using this FDA-approved GRP receptor antagonist for neuroblastoma," Chung said. "We hope to demonstrate the safety of targeting GRP receptors for effective inhibition of neuroblastoma growth and metastasis. This is just such a tragic disease, and with all the advances we're making, we ought to be able to make a dent in it."


'/>"/>

Contact: Jim Kelly
jpkelly@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston
Source:Eurekalert

Related medicine news :

1. Experiments Get Close to Out-of-Body Experience
2. Physical Frailty Could Predict Alzheimers Disease
3. Breast CT Scans Could Be Comfortable Alternative to Mammograms
4. Gene Test Could Catch Deadly Heart Problem
5. Pill Could Boost Sports Performance
6. Liver damage in hepatitis C patients could be treated with warfarin, says study
7. Gene Could Boost Stroke Risk for Migraine Sufferers
8. Being Single in Midlife Could Raise Risk for Dementia Later
9. New Research on Genetic Changes in Melanomas and Teens Use of Indoor Tanning Could Lead to Better Prevention and Treatment Strategies
10. American Academy of Dermatology: Dermatologists Warn Ceramic Flat Irons Could Damage Hair and Lead to Hair Breakage
11. Prostate Cancer Treatment Could Impair Mens Thinking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... PA (PRWEB) , ... May 31, 2016 , ... More ... Philadelphia, Hep B United Philadelphia, and the Prevent Cancer Foundation held an event on ... silent epidemic in the city of viral hepatitis, the leading cause of liver cancer. ...
(Date:5/31/2016)... ... May 31, 2016 , ... Splashtop Inc., the worldwide leader in ... Networks Co., the leading provider of secure mobile remote access solution for Japan ... leading CACHATTO remote access solution. Splashtop for CACHATTO will be available as ...
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices ... But this approach has proven transformative, both for people who hear voices and for ... is used around the world, but it still lags in the United States. , ...
(Date:5/31/2016)... ... May 31, 2016 , ... When ... he knew it was something that contractors should have at their disposal on ... gets,” says Butch, CertainTeed’s Director of Contractor Programs. , As a result, ...
(Date:5/31/2016)... ... May 31, 2016 , ... CallTrackingMetrics's software ... campaigns, to monitor the performance of sales and support staff, and to efficiently ... The software allows customers to record, transcribe, route, document, and report on everything ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 26, 2016 According to a new ... Market - U.S. Industry Analysis, Size, Share, Growth, Trends, and ... the U.S. was valued at US$ 5.89 Bn in 2014 ... from 2015 to 2023 to reach US$ 7.99 Bn in ... and emerging needle free drug delivery devices and the market ...
(Date:5/26/2016)... 26, 2016 TARE (Transarterial ... Cost Savings and Overall Decreased Use of ... an international specialist healthcare company, has today announced ... Annual Meeting of ISPOR (International Society for Pharmacoeconomics ... carcinoma (HCC) using yttrium-90 glass microspheres is associated ...
(Date:5/26/2016)... , May 26, 2016 ... has matured into an essential life science tool for ... development applications. BCC Research reveals in its new report ... second growth phase, one powered by a range of ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
Breaking Medicine Technology: